Recipharm has signed a Memorandum of Understanding for the fill-finish of biotherapeutics and vaccines in Morocco.    Contract development manufacturing organization (CDMO) Recipharm signed the Memorandum of Understanding (MOU) with the King of Morocco, various Moroccan banks, and the Moroccan Government. As part of the MOU, approximately $500 million will be invested by the Moroccan government and others over the next five years to secure capacity and capability for the production of vaccines and biotherapeutics in Morocco. Recipharm will operate…

Rentschler will expand production capacity at its Laupheim, Germany facility to support the increasing demand for complex antibodies. A report published by vfa bio and Boston Consulting Group assessing the state of biotech in Germany revealed the country is falling behind in production capacity when compared globally to others.  to other countries. “While companies in the US, South Korea, Ireland, and Switzerland have expanded their production facilities in the last three years, there has been no growth at all in…

CDMO AGC Bio has picked up a second site in Colorado, buying a cell and gene therapy facility in Longmont from Novartis. The 622,000 square-foot facility in Longmont – north of Denver, Colorado – will become part of AGC Biologics’ ever-growing manufacturing footprint, and will go hand-in-hand with its cell and gene therapy site in Milan, Italy, added through the €240 million ($284 million) acquisition of Molmed last year. “The Longmont facility fits perfectly into AGC’s long-term growth and expansion…

Lonza says the expansion of its high potency API facility in Nansha, China will help support growing demand for ADC production. Swiss contract development manufacturing organization (CDMO) Lonza will add three 1,000 L GMP trains, including development laboratories with the capacity to produce small scale batches of highly potent APIs (HPAPIs). The expanded site will also boast six 1,000 L small molecule reactors, four 1,500L vessels, and isolation equipment adding capacity for a smooth transition between early-phase and large-scale commercial…

Viralgen has opened an $83 million AAV production site in San Sebastian, the first gene therapy production facility in Spain. Contract development and manufacturing organization (CDMO) Viralgen said in November 2019 it would be constructing Spain’s first commercial gene therapy production site at the Miramon Technology Park in San Sebastian to add capacity for gene therapy manufacturing services. The president of the Basque Government in Spain, Iñigo Urkullu and Pedro Duque, Minister of Science and Innovation of the Spanish government opened the facility…

GCT Catapult will construct offices and laboratories in Edinburgh, Scotland to support the cell and gene therapy sector and drive product development. The Cell and Gene Therapy Catapult (CGT Catapult) aims to give additional regional support to the cell and gene therapy industry across the UK, which will drive product development, adoption, and clinical trials. CGT Catapult Edinburgh is a partnership with the University of Edinburgh and will be placed at the Institute for Regeneration and Repair located at Edinburgh…

The facility in New Albany, Ohio will support assembly and packaging for a range of Amgen’s medicines, the firm says. The $365 million investment will see Amgen construct a 270,000 square-foot facility in New Albany, creating around 400 jobs ranging from technicians, engineers, quality assurance, quality control, administrative and management positions. “The facility will assemble, label and package vials and syringes for a wide variety of Amgen medicines,” Amgen spokeswoman Megan Fox told BioProcess Insider. “This new final product advanced…

Fujifilm Diosynth Biotechnologies (FDB) will double cell culture production for recombinant vaccines in the US and increase gene therapy production in the UK ten-fold as part of its latest investment plans. The ¥90 billion ($850 million) expansion will increase capacity across a range of modalities on both sides of the Atlantic. As well as doubling cell culture production for recombinant vaccines in the US, the firm will grow capacity at its Teeside, UK site to increase gene therapy production ten-fold,…